Magnetic Resonance Imaging–guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies

Lam, 2019, EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study), Eur Urol, 76, 790, 10.1016/j.eururo.2019.09.020 Bokhorst, 2015, Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers, Eur Urol, 68, 814, 10.1016/j.eururo.2015.06.012 Loeb, 2016, How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States, J Urol, 196, 721, 10.1016/j.juro.2016.02.2963 Mottet, 2021 National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. London, UK: NICE; 2019. http://www.nice.org.uk/guidance/ng131. Klotz, 2019, Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial, Eur Urol, 75, 300, 10.1016/j.eururo.2018.06.025 Klotz, 2020, Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up, Eur Urol, 77, 311, 10.1016/j.eururo.2019.10.007 Luiting HB, Remmers S, Valdagni R, et al. What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study. Prostate Cancer Prostat Dis. In press. https://doi.org/10.1038/s41391-021-00343-2. Amin, 2020, The Magnetic Resonance Imaging in Active Surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies, J Urol, 203, 910, 10.1097/JU.0000000000000693 Schoots, 2018, Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease, Transl Androl Urol, 7, 132, 10.21037/tau.2017.12.29 Jayadevan, 2019, Magnetic resonance imaging-guided confirmatory biopsy for initiating active surveillance of prostate cancer, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.11019 Chu CE, Cowan JE, Lonergan PE, et al. Diagnostic accuracy and prognostic value of serial prostate multiparametric magnetic resonance imaging in men on active surveillance for prostate cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2020.11.007. Stavrinides, 2020, Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study, Eur Urol, 78, 443, 10.1016/j.eururo.2020.03.035 Selvadurai, 2013, Medium-term outcomes of active surveillance for localised prostate cancer, Eur Urol, 64, 981, 10.1016/j.eururo.2013.02.020 Yamamoto, 2016, Metastatic prostate cancer in men initially treated with active surveillance, J Urol, 195, 1409, 10.1016/j.juro.2015.11.075 Moore, 2017, Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations—a report of a European School of Oncology task force, Eur Urol, 71, 648, 10.1016/j.eururo.2016.06.011 Giganti, 2021, The importance of being PRECISE in prostate magnetic resonance imaging and active surveillance, Eur Urol, 79, 560, 10.1016/j.eururo.2021.01.016 Rajwa P, Pradere B, Quhal F, et al. Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.05.001.